Skip to main content
Premium Trial:

Request an Annual Quote

BARDA Exercises $6.4M Option on T2 Biosystems Contract

NEW YORK – T2 Biosystems announced on Monday that the Biomedical Advanced Research and Development Authority, or BARDA, has exercised a contract option, which will provide the firm an additional $6.4 million of funding.

BARDA, which is part of the office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services, specifically exercised contract Option 2A of a multiple year cost share contract with a total potential value of $69 million if all contract options are exercised.

The initial contract was awarded in 2019 and BARDA exercised the first option, valued at $10.4 million, in September 2020.

The funding will be used to further development of the T2Resistance Panel, which is a direct-from-blood test designed to detect antibiotic resistance genes associated with sepsis-causing pathogens. The funding will also support development of the firm's T2Biothreat Panel to detect pathogens such as B. anthracis, F. tularensis, Y. pestis, Burkholderia spp., and R. prowazekii directly from blood.

In addition, the funding supports development of a comprehensive direct-from-blood sepsis panel designed to cover up to 99 percent of all bloodstream infections by providing more than 36 reported results, as well as a fully automated, random access, high-throughput next-generation instrument.

"We believe the continued funding commitment from BARDA is a testament to our technology and its potential to transform the diagnosis and management of patients at risk of sepsis, reduce antimicrobial resistance, and protect our nation from biothreat pathogens," said John Sperzel, chairman and CEO of T2 Biosystems, in a statement.

The firm plans to initiate US clinical trials for T2Resistance and T2Biothreat Panels using the new funding, Sperzel added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.